Lantheus Holdings Inc
LNTH
ISIN US5165441032 / Valor 24784644
Lantheus Holdings Inc
UMushroom community rating:
About company
Lantheus Holdings Inc. is a prominent player in the healthcare sector, specializing in the development, manufacture, and commercialization of innovative diagnostic and therapeutic agents and products. The company focuses on radiopharmaceuticals and contrast media agents, which are critical in medical imaging and diagnostics. With over 30 years of experience, Lantheus demonstrates a strong track record in managing the global research and development of products across all phases, from discovery through to post-marketing life cycle management. The appointment of Jean-Claude Provost, MD, as Chief Medical Officer underscores the company's commitment to advancing its portfolio of diagnostic and therapeutic solutions. Additionally, under the leadership of Linda Lennox as Vice President, Corporate Communications and Chief of Staff, Lantheus emphasizes the importance of effective internal and external communication strategies, investor relations, and patient advocacy, aligning these efforts with the company's vision, mission, and goals. Lantheus Holdings Inc. thus plays a crucial role in enhancing patient outcomes through its specialized healthcare solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.08.2024):
Revenue Growth
Lantheus Holdings Inc. reported a 23.0% increase in worldwide revenue for the first quarter of 2024, reaching $370.0 million compared to $300.8 million in the same period in 2023. This growth was primarily driven by net product sales of PYLARIFY and DEFINITY.
Net Income
For the first quarter of 2024, Lantheus Holdings Inc. achieved a GAAP net income of $131.1 million, a significant turnaround from a net loss of $2.8 million in the first quarter of 2023. This represents a remarkable improvement in the company's profitability.
Earnings Per Share
Lantheus Holdings Inc. reported a GAAP fully diluted net income per share of $1.87 for the first quarter of 2024, compared to a GAAP fully diluted net loss per share of $0.04 in the same period of 2023. Adjusted fully diluted net income per share increased to $1.69 from $1.47 in the first quarter of 2023.
Operating Income
Operating income for Lantheus Holdings Inc. in the first quarter of 2024 was $106.6 million, a significant improvement from a loss of $9.3 million in the prior year period. Adjusted operating income (non-GAAP) increased by 9.4% to $155.3 million, compared to $142.0 million in the first quarter of 2023.
Cash Flow
In the first quarter of 2024, Lantheus Holdings Inc. reported net cash provided by operating activities of $127.2 million and free cash flow of $119.0 million. The company's cash and cash equivalents grew to $718.3 million as of March 31, 2024, compared to $713.7 million at the end of 2023.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
7328 M
Market cap (USD)
148,318
Daily traded volume (Shares)
107.64 / 105.23
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Tej Ram Kumpakha
EQUITIES OF THE SAME SECTOR
